Pharmacological interplay between breast cancerresistance protein and gefitinib in epidermalgrowth factor receptor signaling

Kazuhiro Katayama, Kazuhiko Shibata, Junko Mitsuhashi, Kohji Noguchi, Yoshikazu Sugimoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: It has been previously shown that gefitinib reverses breast cancer resistance protein (BCRP)-mediated drug resistance. Here, the impact of BCRP on gefitinib-mediated inhibition in epidermal growth factor receptor (EGFR) signaling is evaluated. Materials and Methods: Sensitivity to gefitinib was determined by growth inhibition assay, and intracellular gefitinib levels were measured with HPLC. Western blotting was performed to detect EGFR signaling molecules. Results: BCRP reduced intracellular gefitinib levels and attenuated inhibitory activities of gefitinib to EGF-dependent EGFR signalings including downstream MAPK and Akt pathways in gefitinib- sensitive PC-9 cells. However, gefitinib did not inhibit MAPK and Akt signalings in KB-3-1 and HCT-116 cells, and BCRP- mediated gefitinib-resistance shown in PC-9 cells was not observed in gefitinib-insensitive KB-3-1 and HCT-116 cells. Conclusion: BCRP transports gefitinib and suppresses its inhibitory effects on EGFR phosphorylation. However, effects of BCRP on gefitinib activity in the EGFR signaling and on gefitinib-resistance were limited in the gefitinib-sensitive cells only.

Original languageEnglish
Pages (from-to)1059-1066
Number of pages8
JournalAnticancer Research
Volume29
Issue number4
Publication statusPublished - 2009 Apr

Fingerprint

Breast
Pharmacology
Proteins
Epidermal Growth Factor Receptor
Breast Neoplasms
HCT116 Cells
gefitinib
Protein Transport
Drug Resistance
Epidermal Growth Factor
Western Blotting
High Pressure Liquid Chromatography
Phosphorylation

Keywords

  • BCRPABCG2
  • EGFR
  • Gefitinib
  • HPLC

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pharmacological interplay between breast cancerresistance protein and gefitinib in epidermalgrowth factor receptor signaling. / Katayama, Kazuhiro; Shibata, Kazuhiko; Mitsuhashi, Junko; Noguchi, Kohji; Sugimoto, Yoshikazu.

In: Anticancer Research, Vol. 29, No. 4, 04.2009, p. 1059-1066.

Research output: Contribution to journalArticle

Katayama, Kazuhiro ; Shibata, Kazuhiko ; Mitsuhashi, Junko ; Noguchi, Kohji ; Sugimoto, Yoshikazu. / Pharmacological interplay between breast cancerresistance protein and gefitinib in epidermalgrowth factor receptor signaling. In: Anticancer Research. 2009 ; Vol. 29, No. 4. pp. 1059-1066.
@article{6b471858836548ed8e313783f15e4386,
title = "Pharmacological interplay between breast cancerresistance protein and gefitinib in epidermalgrowth factor receptor signaling",
abstract = "Background: It has been previously shown that gefitinib reverses breast cancer resistance protein (BCRP)-mediated drug resistance. Here, the impact of BCRP on gefitinib-mediated inhibition in epidermal growth factor receptor (EGFR) signaling is evaluated. Materials and Methods: Sensitivity to gefitinib was determined by growth inhibition assay, and intracellular gefitinib levels were measured with HPLC. Western blotting was performed to detect EGFR signaling molecules. Results: BCRP reduced intracellular gefitinib levels and attenuated inhibitory activities of gefitinib to EGF-dependent EGFR signalings including downstream MAPK and Akt pathways in gefitinib- sensitive PC-9 cells. However, gefitinib did not inhibit MAPK and Akt signalings in KB-3-1 and HCT-116 cells, and BCRP- mediated gefitinib-resistance shown in PC-9 cells was not observed in gefitinib-insensitive KB-3-1 and HCT-116 cells. Conclusion: BCRP transports gefitinib and suppresses its inhibitory effects on EGFR phosphorylation. However, effects of BCRP on gefitinib activity in the EGFR signaling and on gefitinib-resistance were limited in the gefitinib-sensitive cells only.",
keywords = "BCRPABCG2, EGFR, Gefitinib, HPLC",
author = "Kazuhiro Katayama and Kazuhiko Shibata and Junko Mitsuhashi and Kohji Noguchi and Yoshikazu Sugimoto",
year = "2009",
month = "4",
language = "English",
volume = "29",
pages = "1059--1066",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Pharmacological interplay between breast cancerresistance protein and gefitinib in epidermalgrowth factor receptor signaling

AU - Katayama, Kazuhiro

AU - Shibata, Kazuhiko

AU - Mitsuhashi, Junko

AU - Noguchi, Kohji

AU - Sugimoto, Yoshikazu

PY - 2009/4

Y1 - 2009/4

N2 - Background: It has been previously shown that gefitinib reverses breast cancer resistance protein (BCRP)-mediated drug resistance. Here, the impact of BCRP on gefitinib-mediated inhibition in epidermal growth factor receptor (EGFR) signaling is evaluated. Materials and Methods: Sensitivity to gefitinib was determined by growth inhibition assay, and intracellular gefitinib levels were measured with HPLC. Western blotting was performed to detect EGFR signaling molecules. Results: BCRP reduced intracellular gefitinib levels and attenuated inhibitory activities of gefitinib to EGF-dependent EGFR signalings including downstream MAPK and Akt pathways in gefitinib- sensitive PC-9 cells. However, gefitinib did not inhibit MAPK and Akt signalings in KB-3-1 and HCT-116 cells, and BCRP- mediated gefitinib-resistance shown in PC-9 cells was not observed in gefitinib-insensitive KB-3-1 and HCT-116 cells. Conclusion: BCRP transports gefitinib and suppresses its inhibitory effects on EGFR phosphorylation. However, effects of BCRP on gefitinib activity in the EGFR signaling and on gefitinib-resistance were limited in the gefitinib-sensitive cells only.

AB - Background: It has been previously shown that gefitinib reverses breast cancer resistance protein (BCRP)-mediated drug resistance. Here, the impact of BCRP on gefitinib-mediated inhibition in epidermal growth factor receptor (EGFR) signaling is evaluated. Materials and Methods: Sensitivity to gefitinib was determined by growth inhibition assay, and intracellular gefitinib levels were measured with HPLC. Western blotting was performed to detect EGFR signaling molecules. Results: BCRP reduced intracellular gefitinib levels and attenuated inhibitory activities of gefitinib to EGF-dependent EGFR signalings including downstream MAPK and Akt pathways in gefitinib- sensitive PC-9 cells. However, gefitinib did not inhibit MAPK and Akt signalings in KB-3-1 and HCT-116 cells, and BCRP- mediated gefitinib-resistance shown in PC-9 cells was not observed in gefitinib-insensitive KB-3-1 and HCT-116 cells. Conclusion: BCRP transports gefitinib and suppresses its inhibitory effects on EGFR phosphorylation. However, effects of BCRP on gefitinib activity in the EGFR signaling and on gefitinib-resistance were limited in the gefitinib-sensitive cells only.

KW - BCRPABCG2

KW - EGFR

KW - Gefitinib

KW - HPLC

UR - http://www.scopus.com/inward/record.url?scp=64949108700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949108700&partnerID=8YFLogxK

M3 - Article

C2 - 19414346

AN - SCOPUS:64949108700

VL - 29

SP - 1059

EP - 1066

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -